Interval between planning and frameless stereotactic radiosurgery for brain metastases: are our margins still accurate?

Charlotte Bronnimann(Centre Hospitalier Universitaire de Bordeaux), V. Vendrely(Centre Hospitalier Universitaire de Bordeaux), R. Trouette(Centre Hospitalier Universitaire de Bordeaux), E. Blais(Centre Hospitalier Universitaire de Bordeaux), A. Huchet(Centre Hospitalier Universitaire de Bordeaux), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), J. Benech-Faure(Centre Hospitalier Universitaire de Bordeaux), Olivier Saut(Centre National de la Recherche Scientifique), Olivier Mollier(Centre Hospitalier Universitaire de Bordeaux)
Neuro-Oncology Practice
October 1, 2019
10.1093/nop/npz048
Cited by 7

Related Papers

Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Combined Vemurafenib and Cobimetinib in <i>BRAF</i> -Mutated Melanoma
|New England Journal of Medicine|2014|2k
Adjuvant Dabrafenib plus Trametinib in Stage III<i>BRAF</i>-Mutated Melanoma
|New England Journal of Medicine|2017|1.5k
Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|1.3k
Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2018|1k